Top

Cancer Chemotherapy and Pharmacology

Published in:

01-02-2018 | Original Article

Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis

Authors: Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2018

Abstract

Purpose

Multidrug resistance mediated by ABCB1 has been perceived to be one of the obstacles for cancer chemotherapy. This meta-analysis was performed to verify the effect of the ABCB1 rs1045642 and rs1128503 polymorphisms on the response to Taxane-containing chemotherapy.

Methods

Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were employed to evaluate the impact of these two ABCB1 polymorphisms. R scripts were developed to perform the meta-analysis.

Results

A total of nine articles (including nine studies for rs1045642 and five for rs1128503) were collected in our systematic review. However, our meta-analysis showed no significant effect of these two ABCB1 polymorphisms on the response to Taxane-containing regimens.

Conclusions

This study highlights the unsuitability of relying on the ABCB1 rs1045642 and rs1128503 polymorphisms as therapeutic response biomarkers of Taxane-containing chemotherapy. Further polycentric studies in larger and multiracial populations are needed to validate the conclusions.

Leschziner GD, Andrew T, Pirmohamed M, Johnson MR (2006) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7(3):154–179CrossRefPubMed

Wu C-P, Hsieh C-H, Wu Y-S (2011) The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm 8(6):1996–2011CrossRefPubMed

Wang R, Sumarpo A, Saiki Y, Chen N, Sunamura M, Horii A (2016) ABCB1 is upregulated in acquisition of taxane resistance: lessons from esophageal squamous cell carcinoma cell lines. Tohoku J Exp Med 240(4):295–301CrossRefPubMed

Hansen SN, Westergaard D, Thomsen MBH et al (2015) Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumor Biol 36(6):4327–4338CrossRef

Boora GK, Kanwar R, Kulkarni AA et al (2016) Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5(4):631–639. https://doi.org/10.1002/cam4.625 CrossRefPubMedPubMedCentral

Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55(3):425–461CrossRefPubMed

Hitzl M, Drescher S, van der Kuip H et al (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells. Pharmacogenetics 11(4):293–298CrossRefPubMed

Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473–3478CrossRefPubMedPubMedCentral

Caronia D, Patiño-Garcia A, Peréz-Martínez A et al (2011) Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a Pharmacogenetic Study. PLOS One 6(10):e26091. https://doi.org/10.1371/journal.pone.0026091 CrossRefPubMedPubMedCentral

10.

Schaich M, Kestel L, Pfirrmann M et al (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20(1):175–181. https://doi.org/10.1093/annonc/mdn548 CrossRefPubMed

11.

Schwarzer G (2007) Meta: an R package for meta-analysis. R News 7(3):40–45

12.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

13.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

14.

Galbraith R (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7(8):889–894CrossRefPubMed

15.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentral

16.

Chang H, Rha SY, Jeung HC et al (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20(2):272–277CrossRefPubMed

17.

Choi JR, Kim J-O, Kang DR et al (2015) Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat 47(3):509–517CrossRefPubMed

18.

Grau JJ, Caballero M, Campayo M et al (2009) Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 119(8):1484–1490CrossRefPubMed

19.

Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15(8):1194–1203CrossRefPubMed

20.

Lévy P, Gligorov J, Antoine M et al (2013) Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 139(2):421–428CrossRefPubMed

21.

Pan J-h, Han J-x, Wu J-m, Huang H-n Yu Q-Z, Sheng L-J (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78(1):49–55CrossRefPubMed

22.

Qiao R, Wu W, Lu D, Han B (2016) Influence of single nucleotide polymorphisms in ABCB1, ABCG2 and ABCC2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer. Int J Clin Exp Med 9(1):298–307

23.

Shim HJ, Yun JY, Hwang JE et al (2010) BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 101(5):1247–1254CrossRefPubMed

24.

Tulsyan S, Chaturvedi P, Singh AK et al (2014) Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene 543(1):69–75CrossRefPubMed

25.

Wang J, Tang J, Zhong S et al (2011) Association between MDR1 gene polymorphisms and curative effect of taxane-anthracycline chemotherapy in breast cancer. Chin J Clin Oncol 38(1):15–19

26.

Zhou J, Deng W, Gao J, Yuan J, Li Y, Shen L (2015) Association between ABCB1 G2677T/A polymorphisms and chemosensitivity of paclitaxel in advanced gastric cancer. Chin J Gastrointest Surg 18(2):123–126

27.

Hertz DL, Rae J (2015) Pharmacogenetics of cancer drugs. Annu Rev Med 66:65–81CrossRefPubMed

28.

Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3(12):912–920CrossRefPubMed

29.

Rodriguez-Antona C, Taron M (2015) Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med 277(2):201–217CrossRefPubMed

30.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in Medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 357(21):2189–2194CrossRefPubMed

31.

Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G (2013) Meta-analysis: pitfalls and hints. Heart Lung Vessels 5(4):219–225PubMedPubMedCentral

32.

Walker E, Hernandez AV, Kattan MW (2008) Meta-analysis: Its strengths and limitations. Clevel Clinic J Med 75(6):431–439CrossRef

Title: Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
Authors: Qi Jiang
Meizhen Xu
Yina Liu
Yudi Chen
Jiarong Feng
Xuelin Wang
Shuang Liang
Dan Li
Xiaoqin Yang
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3496-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study

B7-H3 in tumors: friend or foe for tumor immunity?

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting

CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer